The Unique Properties and Classification of Stem Cells

Every cell in the human body – from the neurons firing in your brain to the red blood cells carrying oxygen – began as something far simpler: a stem cell. What makes stem cells extraordinary is not just what they are, but what they can become. The degree to which a stem cell can transform into other cell types is called its potency, and understanding potency is fundamental to grasping both the promise and the limits of modern stem cell science. This classification – into totipotent, pluripotent, and multipotent cells – shapes everything from how we study disease to how we design therapies.

What is cell potency? 🔗

Before exploring the types, it helps to understand the concept of potency itself. Cell potency refers to the varying ability of stem cells to differentiate into specialized cell types. Cells with the greatest potency can generate more cell types than those with lower potency. Think of it as a spectrum: at one end sits a cell that can become anything; at the other, a cell locked into producing only one type of tissue. This hierarchy is not arbitrary – it mirrors the natural progression of embryonic development, from a freshly fertilized egg to a fully formed organism.

According to a peer-reviewed study published in Frontiers in Cell and Developmental Biology, the traditional developmental pathway follows the differentiation of totipotent stem cells into pluripotent stem cells, then into multipotent stem cells, and finally into mature, specialized cells. Both self-renewal capacity and differentiation potential decrease at each stage of this journey.

Totipotent stem cells: maximum potential 🔗

The prefix toti- comes from the Latin word for “whole” or “entire,” and that etymology is fitting. Totipotent stem cells can differentiate into all the cell types necessary to form a complete organism – including embryonic tissues and organs outside the embryo, such as the placenta. This makes them the most powerful cells in the biological hierarchy.

The classic example is the zygote – the fertilized egg formed when a sperm and egg cell fuse. These cells are produced from the fusion of an egg and sperm cell, and cells produced by the first few divisions of the fertilized egg are also totipotent. In human embryos, totipotency is generally maintained up to around the 16-cell stage, roughly four days after fertilization. After this point, cells begin to specialize and lose their absolute developmental potential.

Totipotent cells are capable of giving rise to any of the approximately 220 cell types found in an embryo, as well as the extra-embryonic structures that support fetal development. However, despite this extraordinary potential, totipotent cells are rarely used directly in therapy. Maintaining their developmental totipotency and self-renewal capacity in culture remains a key limiting factor in research, and the ethical concerns tied to early embryo use add another layer of restriction.

Pluripotent stem cells: almost unlimited differentiation 🔗

Once a human embryo reaches the blastocyst stage – typically five to seven days after fertilization – a cluster of cells forms inside called the inner cell mass. These cells are pluripotent. Embryonic stem cells derived from this inner cell mass are pluripotent, capable of developing into any cell type in an adult body – with one key exception: they cannot form the placenta or other extra-embryonic structures. That single limitation distinguishes them from totipotent cells.

Pluripotent stem cells are often described as “true stem cells” because of this near-universal differentiation capacity. They are classified into embryonic stem cells, perinatal stem cells, and induced pluripotent stem cells based on their tissue of origin. Each subtype has its own source, advantages, and ethical considerations.

Embryonic stem cells (ESCs) 🔗

Embryonic stem cells are derived from the inner cell mass of the blastocyst. ESCs have the ability to divide indefinitely in vivo, unlike adult stem cells, which divide only during tissue damage or cell death. This makes them extraordinarily valuable for research, but their derivation requires the destruction of a human embryo – a fact that has generated sustained ethical and political controversy globally. ESC research is laden with ethical concerns, particularly regarding ideas of personhood and human dignity that arise from dealing with human life in one of its earliest forms.

Perinatal stem cells 🔗

Perinatal stem cells are derived from umbilical cord blood and are among the most widely used pluripotent stem cells. Because they are collected from tissue that is otherwise discarded after birth, they carry far fewer ethical concerns than embryonic stem cells. Cord blood banking – the practice of storing these cells at birth for potential future therapeutic use – is increasingly accepted as a practical option for treating complex disorders later in life.

Induced pluripotent stem cells (iPSCs) 🔗

Perhaps the most significant development in recent stem cell research is the creation of induced pluripotent stem cells (iPSCs). iPSCs are adult cells reprogrammed artificially to behave like embryonic stem cells, with the advantage of a reduced chance of graft rejection since they use somatic cells from the same individual. In 2006, Shinya Yamanaka generated iPSCs by reprogramming adult somatic cells through the expression of specific pluripotency transcription factors – a breakthrough that earned him the 2012 Nobel Prize in Physiology or Medicine.

iPSCs avoid the moral controversy tied to embryo destruction while offering many of the same scientific advantages as ESCs. Some researchers have argued that iPSC technology makes embryonic stem cell research no longer necessary, though others note that ESCs remain essential as a benchmark for quality control and comparison. The question of whether iPSCs are fully equivalent to ESCs – and whether they carry their own moral status if they could theoretically be used to generate a complete embryo – remains an active area of philosophical and scientific debate.

Multipotent stem cells: specialized and targeted 🔗

Further along the potency spectrum sit multipotent stem cells. These are the workhorses of the adult body. Multipotent stem cells can differentiate into a number of cell types, but only those of a closely related family of cells. They are not capable of producing just any cell in the body – their developmental range is narrower and tissue-specific.

A key example is the hematopoietic stem cell (HSC), found in bone marrow. HSCs can differentiate into all major types of blood cells – red blood cells, white blood cells, and platelets. Similarly, mesenchymal stem cells (MSCs), found in bone marrow and adipose tissue, can give rise to connective tissue cells such as bone, cartilage, and fat cells.

While multipotent cells have a more limited range than pluripotent ones, this is not a disadvantage in clinical settings. Multipotent stem cells are in fact the category most often used in regenerative medicine, precisely because their narrower differentiation range makes them more controllable and clinically safer than higher-potency cells, which carry a greater risk of forming teratomas (abnormal tumors).

Oligopotent and unipotent cells 🔗

Below multipotency, two additional levels of potency exist, though their clinical applications remain limited. Oligopotent stem cells can differentiate into only a few closely related cell types – myeloid and lymphoid stem cells are classic examples, capable of producing certain blood and immune cells respectively. Unipotent stem cells can produce only a single cell type, but unlike fully differentiated cells, they retain the capacity for self-renewal – a property that still makes them biologically significant for tissue maintenance and repair.

Why potency classification matters for medicine 🔗

The classification of stem cells by potency is not merely an academic exercise – it directly shapes how stem cells can be used in research and therapy. Stem cells’ regenerative potential spans embryonic, adult, induced pluripotent, and perinatal stages, offering therapeutic opportunities in cancer, neurodegenerative disorders, cardiovascular diseases, spinal cord injuries, diabetes, and tissue damage.

People who might benefit from stem cell therapies include those with leukemia, Hodgkin disease, non-Hodgkin lymphoma, aplastic anemia, and inherited metabolic conditions. Stem cells are also being actively studied for type 1 diabetes, Parkinson’s disease, heart failure, and osteoarthritis. In drug development, researchers use stem cells to test new drugs for safety and quality before human trials – a process that could reduce both cost and ethical concerns around animal testing.

Recent regulatory milestones reflect the accelerating pace of this field. In December 2024, Ryoncil received FDA approval as the first mesenchymal stem cell therapy for pediatric steroid-refractory acute graft-versus-host disease – a life-threatening condition following bone marrow transplantation. Meanwhile, as of late 2024, a major review identified 115 global clinical trials involving 83 distinct pluripotent stem cell-derived products targeting conditions in ophthalmology, neurology, and oncology.

The philosophical dimension: potency, personhood, and ethics 🔗

The potency classification of stem cells is not only a scientific matter – it carries deep philosophical weight. The ethical debate around totipotent and pluripotent stem cells in particular centers on the question of what constitutes a human life and when it begins. If a stem cell carries the theoretical potential to develop into a complete human organism, many argue it deserves a corresponding degree of moral protection – a question that becomes even more complex with iPSCs, which can be derived from ordinary skin or blood cells.

The International Society for Stem Cell Research (ISSCR), the largest professional body in the field, has established international guidelines and ethical standards to govern how stem cell research is conducted, aiming to balance scientific progress with moral responsibility. The broader question – of who should have access to these therapies, at what cost, and under what conditions – remains one of the central concerns at the intersection of philosophy, technology, and medicine.

The discovery of iPSCs offered one path through this ethical minefield. By reprogramming adult cells to revert to a stem cell-like state, iPSCs offer a promising alternative that bypasses ethical concerns around embryo destruction, making stem cell research more accessible and more widely accepted. Yet new questions have emerged in their place – around genetic manipulation, informed consent for cell donors, and the risk of creating organisms with ambiguous moral status through chimeric research.

Understanding how stem cells are classified, and why those classifications matter, is the first step toward engaging meaningfully with these questions – both as scientists and as citizens navigating the ethical frontiers of biotechnology.

What do you think? If an induced pluripotent stem cell can theoretically be reprogrammed to develop into a complete organism, should it be granted the same moral status as an embryo? And as stem cell therapies grow more effective, how should societies decide who gets access to them – and at what cost?

References

1. https://www.technologynetworks.com/cell-science/articles/cell-potency-totipotent-vs-pluripotent-vs-multipotent-stem-cells-303218
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC5118841/
3. https://celltexbank.com/blog-stem-cell-types/
4. https://en.wikipedia.org/wiki/Stem_cell
5. https://int.livhospital.com/pluripotent-vs-totipotent-stem-cells-key-differences/
6. https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/cell-culture-and-cell-culture-analysis/stem-cell-culture/what-are-stem-cells
7. https://embryo.asu.edu/pages/ethics-and-induced-pluripotent-stem-cells
8. https://link.springer.com/article/10.1186/s13287-019-1455-y
9. https://www.eurostemcell.org/ethics-and-reprogramming-ethical-questions-after-discovery-ips-cells
10. https://getwellgo.com/post/totipotent-vs-pluripotent-vs-multipotent-stem
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC11634165/
12. https://www.mayoclinic.org/tests-procedures/bone-marrow-transplant/in-depth/stem-cells/art-20048117
13. https://www.reprocell.com/blog/current-landscape-of-fda-stem-cell-approvals-and-trials-2023-2025
14. https://www.isscr.org/
15. https://www.openaccessjournals.com/articles/induced-pluripotent-stem-cells-ipscs-the-ethical-alternative-18252.html